#NASDAQ #Ireland #Medtronic #Galway #MiniMed

MiniMed Group, Inc. Begins Trading on Nasdaq

Medtronic plc, a prominent force in healthcare technology, has announced that its subsidiary, MiniMed Group, Inc., is now publicly traded on the Nasdaq Global Select Market under the ticker symbol "MMED". This move marks a significant milestone, especially for investors and stakeholders involved in the healthcare technology sector.

Geoff Martha, the chairman and CEO of Medtronic, expressed enthusiasm about this development. He commented, "Today marks an exciting milestone for both MiniMed and Medtronic. Despite a challenging market backdrop shaped by geopolitical uncertainty, the teams successfully executed an oversubscribed offering that is the second largest IPO in Medtech history." This remark underscores the robust demand for MiniMed’s offering, reflecting investor confidence even in uncertain times.

The establishment of MiniMed as an independent entity is expected to enhance its agility in the market. Martha highlighted, "Establishing MiniMed as a standalone entity positions the company to operate with greater agility over the long term." This move allows MiniMed to concentrate its operations and resources more effectively while adhering to the strategic vision of Medtronic, which is to leverage its scale and competencies for long-term value creation.

The IPO has garnered a lot of attention, not just due to its scale but also due to the innovative solutions that MiniMed is known for. The company specializes in various healthcare technologies, particularly in devices to help manage diabetes, a growing health challenge worldwide. By going public, MiniMed aims to elevate its presence and capability in healthcare delivery, thereby enhancing patient outcomes worldwide.

About Medtronic and MiniMed
Medtronic, headquartered in Galway, Ireland, operates globally and focuses on alleviating pain, restoring health, and extending life through advanced technology. The leading company has over 95,000 employees working across more than 150 countries, providing solutions for 70 different health conditions. MiniMed is a vital component of this mission, specializing in technologies that significantly improve the lives of diabetes patients through innovation and robust healthcare solutions.

At the core of Medtronic’s success lies its commitment to empowering insight-driven care while placing people at the center of its operations. By launching MiniMed on Nasdaq, Medtronic aims to not only support its ongoing mission but also foster better health outcomes for communities globally.

As both investors and health professionals watch closely, this IPO signifies a promising shift within the medtech sector. MiniMed’s successful debut on Nasdaq is likely to inspire additional investment and innovation in healthcare technologies that aim to tackle some of the most pressing health issues we face today.

Stay tuned for updates as MiniMed charts its path forward amidst the evolving landscape of healthcare technology.